Home / Generics / News / Dr Reddy’s buys six OTC brands from Ducere Pharma

Dr Reddy’s buys six OTC brands from Ducere Pharma Posted 03/06/2016

Generics giant Dr Reddy’s Laboratories (Dr Reddy’s) has entered the US branded consumer health products market by acquiring six over-the-counter (OTC) brands from US-based Ducere Pharma.

India’s second largest drugmaker announced the acquisition of the cough-and-cold, pain and dermatology medicines on 25 May 2016. The brands acquired include pain relievers Bufferin, Doan’s, Myoflex and Nupercainal ointment, as well as toenail fungus treatment Cruex gel and cough and cold treatment Comtrex.

OTC drugs are medicines that can be bought directly by patients without a prescription. The six brands mark Dr Reddy’s entry into the branded consumer health arena. They are sold in over 20,000 US stores and had total US sales of US$8 million in 2015.

Alok Sonig, Executive Vice President and Head of Dr Reddy’s in the US, expects the addition of the brands to grow Dr Reddy’s OTC business in the US.

Rival generics maker Mylan has also been expanding into the OTC arena, with its acquisition of Swedish drugmaker Meda in February 2016 [1].

Related article
Dr Reddy’s and TRPharma collaborate on biosimilars in Turkey

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Mylan to acquire Swedish drugmaker Meda [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jun 3]. Available from: www.gabionline.net/Pharma-News/Mylan-to-acquire-Swedish-drugmaker-Meda

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: Economic Times India

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more